JP2010539076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539076A5 JP2010539076A5 JP2010523590A JP2010523590A JP2010539076A5 JP 2010539076 A5 JP2010539076 A5 JP 2010539076A5 JP 2010523590 A JP2010523590 A JP 2010523590A JP 2010523590 A JP2010523590 A JP 2010523590A JP 2010539076 A5 JP2010539076 A5 JP 2010539076A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- derivative
- reacting
- sorafenib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims description 7
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims 15
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 7
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 7
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229960003787 sorafenib Drugs 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000002585 base Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 150000003672 ureas Chemical class 0.000 claims 5
- RXZZBPYPZLAEFC-UHFFFAOYSA-N 4-(4-aminophenoxy)-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(N)=CC=2)=C1 RXZZBPYPZLAEFC-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical class NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 3
- 150000003931 anilides Chemical class 0.000 claims 3
- -1 trihaloalkyl halide Chemical class 0.000 claims 3
- LLQHVWGFCDKVOP-UHFFFAOYSA-N phenoxyurea Chemical compound NC(=O)NOC1=CC=CC=C1 LLQHVWGFCDKVOP-UHFFFAOYSA-N 0.000 claims 2
- BGVBBMZMEKXUTR-UHFFFAOYSA-N 4-chloro-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC(Cl)=CC=N1 BGVBBMZMEKXUTR-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 1
- 229960000487 sorafenib tosylate Drugs 0.000 claims 1
- 0 *C(Nc(cc1C(F)(F)F)ccc1Cl)=O Chemical compound *C(Nc(cc1C(F)(F)F)ccc1Cl)=O 0.000 description 1
- QUZCXFJNKCWQIU-UHFFFAOYSA-N Oc(cc1)ccc1NC(NC1C=C(C(F)(F)F)C(Cl)=CC1)=O Chemical compound Oc(cc1)ccc1NC(NC1C=C(C(F)(F)F)C(Cl)=CC1)=O QUZCXFJNKCWQIU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1733MU2007 | 2007-09-10 | ||
| IN1733/MUM/2007 | 2007-09-10 | ||
| IN1734/MUM/2007 | 2007-09-10 | ||
| IN1734MU2007 | 2007-09-10 | ||
| PCT/GB2008/003048 WO2009034308A2 (en) | 2007-09-10 | 2008-09-10 | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539076A JP2010539076A (ja) | 2010-12-16 |
| JP2010539076A5 true JP2010539076A5 (cg-RX-API-DMAC7.html) | 2011-10-27 |
| JP5438680B2 JP5438680B2 (ja) | 2014-03-12 |
Family
ID=40351766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523590A Expired - Fee Related JP5438680B2 (ja) | 2007-09-10 | 2008-09-10 | Ｒａｆキナーゼ阻害剤の製造方法及び該方法に使用する中間体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8445687B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2195286A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5438680B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101553211B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008299703C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2698795C (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ583790A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009034308A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201001935B (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
| PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
| PL1626714T3 (pl) | 2003-05-20 | 2007-12-31 | Bayer Healthcare Llc | Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR |
| CA2698795C (en) | 2007-09-10 | 2016-04-19 | Cipla Limited | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
| BRPI0918268B1 (pt) | 2008-09-02 | 2021-08-03 | Novartis Ag | Derivados de picolinamida, seu uso, e composição farmacêutica |
| US8604208B2 (en) | 2009-09-24 | 2013-12-10 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
| AU2010299483B2 (en) | 2009-09-24 | 2014-08-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of sorafenib tosylate |
| WO2011058522A1 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
| PL2528899T3 (pl) | 2010-01-29 | 2015-02-27 | Ranbaxy Laboratories Ltd | Solwat sorafenibu z dimetylosulfotlenkiem |
| CN102190616B (zh) * | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| US9102593B2 (en) * | 2011-01-18 | 2015-08-11 | Glaxo Group Limited | Process for the preparation of retigabine |
| CN102485714B (zh) * | 2011-10-09 | 2013-07-24 | 连云港盛和生物科技有限公司 | 一种羰基化合成索拉菲尼的方法 |
| HK1206021A1 (en) | 2012-05-21 | 2015-12-31 | Novartis Ag | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| CN103408488A (zh) * | 2013-08-13 | 2013-11-27 | 张家港威胜生物医药有限公司 | 一种索拉非尼的优化合成方法 |
| PT3039424T (pt) | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
| CN104761492A (zh) * | 2014-01-03 | 2015-07-08 | 正大天晴药业集团股份有限公司 | 对甲苯磺酸索拉非尼的晶型及其制备方法 |
| CN105481764A (zh) * | 2014-09-16 | 2016-04-13 | 重庆圣华曦药业股份有限公司 | 一种索拉非尼对甲苯磺酸盐的制备方法 |
| CN105399668B (zh) * | 2015-12-29 | 2018-11-16 | 开封制药(集团)有限公司 | 一种“一锅法”制备索拉菲尼的方法 |
| CN105801475B (zh) * | 2016-04-25 | 2018-01-12 | 华润双鹤利民药业（济南）有限公司 | 一种甲苯磺酸索拉非尼的制备方法 |
| CN109796400B (zh) * | 2017-11-16 | 2022-07-29 | 四川科伦药物研究院有限公司 | 一种甲苯磺酸索拉菲尼晶型及其制备方法 |
| CN108623521B (zh) * | 2018-03-22 | 2020-09-04 | 盐城师范学院 | 一种乐伐替尼的制备方法 |
| CN108276328A (zh) * | 2018-03-31 | 2018-07-13 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的制备方法 |
| CN108276327A (zh) * | 2018-03-31 | 2018-07-13 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的制备方法 |
| CN108586329A (zh) * | 2018-03-31 | 2018-09-28 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的合成方法 |
| CN108558747A (zh) * | 2018-03-31 | 2018-09-21 | 山东罗欣药业集团恒欣药业有限公司 | 一种瑞戈非尼的制备方法 |
| CN108341770A (zh) * | 2018-03-31 | 2018-07-31 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼化合物的制备方法 |
| CN108440403A (zh) * | 2018-03-31 | 2018-08-24 | 山东罗欣药业集团恒欣药业有限公司 | 一种瑞戈非尼的制备方法 |
| CN108586330A (zh) * | 2018-04-18 | 2018-09-28 | 日照市普达医药科技有限公司 | 一种治疗肿瘤药物的制备方法及其应用 |
| KR20220038696A (ko) | 2019-07-19 | 2022-03-29 | 아나제네시스 바이오테크놀로지스 에스.에이.에스. | 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL123536C (cg-RX-API-DMAC7.html) * | 1963-07-09 | |||
| FR1484461A (fr) * | 1965-06-25 | 1967-06-09 | Grace W R & Co | Compositions herbicides |
| CH50468A4 (cg-RX-API-DMAC7.html) * | 1968-01-12 | 1970-06-30 | ||
| CH490005A (de) * | 1968-02-06 | 1970-05-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
| BE788983A (fr) * | 1971-09-22 | 1973-01-15 | Rolland Sa A | 3-trifluoromethylanilides |
| US5541224A (en) * | 1994-03-14 | 1996-07-30 | Eli Lilly And Company | Carbanilide anticoccidials |
| RS51497B (sr) * | 1999-01-13 | 2011-04-30 | Bayer Healthcare Llc | w-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6242385B1 (en) * | 2000-02-28 | 2001-06-05 | Uniroyal Chemical Company, Inc. | Enhancement of seed/fruit/nut yields from flowering plants |
| WO2005021534A1 (ja) * | 2003-08-28 | 2005-03-10 | Taisho Pharmaceutical Co., Ltd. | １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体 |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| BRPI0515944B1 (pt) | 2004-09-29 | 2021-11-09 | Bayer Healthcare Llc | Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida |
| TW200730503A (en) * | 2005-10-21 | 2007-08-16 | Daiichi Seiyaku Co | Tricyclic compound |
| CN101466710B (zh) * | 2005-12-02 | 2013-05-29 | 拜尔健康护理有限责任公司 | 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物 |
| CA2698795C (en) | 2007-09-10 | 2016-04-19 | Cipla Limited | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
-
2008
- 2008-09-10 CA CA2698795A patent/CA2698795C/en not_active Expired - Fee Related
- 2008-09-10 US US12/677,195 patent/US8445687B2/en not_active Expired - Fee Related
- 2008-09-10 KR KR1020107007688A patent/KR101553211B1/ko not_active Expired - Fee Related
- 2008-09-10 NZ NZ583790A patent/NZ583790A/en not_active IP Right Cessation
- 2008-09-10 JP JP2010523590A patent/JP5438680B2/ja not_active Expired - Fee Related
- 2008-09-10 EP EP08806217A patent/EP2195286A2/en not_active Ceased
- 2008-09-10 AU AU2008299703A patent/AU2008299703C1/en not_active Ceased
- 2008-09-10 WO PCT/GB2008/003048 patent/WO2009034308A2/en not_active Ceased
-
2010
- 2010-03-18 ZA ZA2010/01935A patent/ZA201001935B/en unknown